GSK plc. Cuts 650 Jobs at Dresden Vaccine Site — Health Care

GSK plc. to Cut 650 Jobs at Dresden Vaccine Facility

GSK plc. confirmed the elimination of 650 positions at its Dresden vaccine manufacturing campus, part of workforce reductions in the Health Care sector reported for September 15–16, 2026. The company is consolidating vaccine manufacturing to its Canada site, according to BioSpace.

Reported Layoffs

• GSK plc. plans to close its Dresden, Germany vaccine manufacturing facility, a move that will affect 650 employees at the site, per reporting by BioSpace. The company tied the closure to a consolidation of vaccine production to Canada and to broader cost-savings measures it announced in July.

• BioSpace’s coverage states the decision is intended to simplify operations and to match anticipated future demand more sustainably and competitively. The report notes related program and pipeline changes at GSK, with the specific layoff impact focused on roles at the Dresden vaccine campus.

Closing

Per BioSpace reporting, the announced workforce reduction at GSK plc. will remove 650 jobs as the company shutters its Dresden vaccine manufacturing site and concentrates production in Canada. This action is recorded among Health Care layoffs and reflected in WARN notices and company communications reported on September 15–16, 2026.